<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CERVIDIL- dinoprostone insert, extended release </strong><br>Forest Laboratories, Inc.<br></p></div>
<h1>CERVIDIL<span class="Sup">®</span><br>Brand of dinoprostone vaginal insert</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">Rev. 10/12       <span class="Bold">Rx only</span>    RMC 226</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system.  Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert.  An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated.  The finished product is a controlled release formulation which has been found to release dinoprostone <span class="Italics">in vivo</span> at a rate of approximately 0.3 mg/hr.</p>
<p>The chemical name for dinoprostone (commonly known as prostaglandin E<span class="Sub">2</span> or PGE<span class="Sub">2</span>) is 11α, 15S-dihydroxy-9-oxo-prosta-5Z,13E-dien-1-oic acid and the structural formula is represented below:</p>
<div class="Figure">
<a name="f1"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f1391c7c-233e-44d8-8838-36cc12f01044&amp;name=cer00-0004-01.jpg">
</div>
<p>The molecular formula is C<span class="Sub">20</span>H<span class="Sub">32</span>O<span class="Sub">5</span> and its molecular weight is 352.5.  Dinoprostone occurs as a white to off-white crystalline powder.  It has a melting point within the range of 65° to 69°C.  Dinoprostone is soluble in ethanol and in 25% ethanol in water.  Each insert contains 10 mg of dinoprostone in 241 mg of a cross-linked polyethylene oxide/urethane polymer which is a semi-opaque, beige colored, flat rectangular slab measuring 29 mm by 9.5 mm and 0.8 mm in thickness.  The insert and its retrieval system, made of polyester yarn, are non-toxic and when placed in a moist environment, absorb water, swell, and release dinoprostone.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Dinoprostone (PGE<span class="Sub">2</span>) is a naturally-occurring biomolecule.  It is found in low concentrations in most tissues of the body and functions as a local hormone (1-3).  As with any local hormone, it is very rapidly metabolized in the tissues of synthesis (the half-life estimated to be 2.5-5 minutes).  The rate limiting step for inactivation is regulated by the enzyme 15-hydroxyprostaglandin dehydrogenase (PGDH) (1,4).  Any PGE<span class="Sub">2</span> that escapes local inactivation is rapidly cleared to the extent of 95% on the first pass through the pulmonary circulation (1,2).</p>
<p>In pregnancy, PGE<span class="Sub">2</span> is secreted continuously by the fetal membranes and placenta and plays an important role in the final events leading to the initiation of labor (1,2).  It is known that PGE<span class="Sub">2</span> stimulates the production of PGF<span class="Sub">2α</span> which in turn sensitizes the myometrium to endogenous or exogenously administered oxytocin.  Although PGE<span class="Sub">2</span> is capable of initiating uterine contractions and may interact with oxytocin to increase uterine contractility, the available evidence indicates that, in the concentrations found during the early part of labor, PGE<span class="Sub">2</span> plays an important role in cervical ripening without affecting uterine contractions (5-7).  This distinction serves as the basis for considering cervical ripening and induction of labor, usually by the use of oxytocin (8-10), as two separate processes.</p>
<p>PGE<span class="Sub">2</span> plays an important role in the complex set of biochemical and structural alterations involved in cervical ripening.  Cervical ripening involves a marked relaxation of the cervical smooth muscle fibers of the uterine cervix which must be transformed from a rigid structure to a softened, yielding and dilated configuration to allow passage of the fetus through the birth canal (11-13).  This process involves activation of the enzyme collagenase which is responsible for digestion of some of the structural collagen network of the cervix (1, 14).  This is associated with a concomitant increase in the amount of hydrophilic glycosaminoglycan, hyaluronic acid and a decrease in dermatan sulfate (1).  Failure of the cervix to undergo these natural physiologic changes, usually assessed by the method described by Bishop (15,16), prior to the onset of effective uterine contractions, results in an unfavourable outcome for successful vaginal delivery and may result in fetal compromise.  It is estimated that in approximately 5% of pregnancies the cervix does not ripen normally (17).  In an additional 10-11% of pregnancies, labor must be induced for medical or obstetric reasons prior to the time of cervical ripening (17).</p>
<p>The delivery rate of PGE<span class="Sub">2</span><span class="Italics">in vivo</span> is about 0.3 mg/hour over a period of 12 hours.  The controlled release of PGE<span class="Sub">2</span> from the hydrogel insert is an attempt to provide sufficient quantities of PGE<span class="Sub">2</span> to the local receptors to satisfy hormonal requirements.  In the majority of patients, these local effects are manifested by changes in the consistency, dilatation and effacement of the cervix as measured by the Bishop score.  Although some patients experience <span class="product-label-link" type="condition" conceptid="192698" conceptname="Hypertonic uterine dysfunction">uterine hyperstimulation</span> as a result of direct PGE<span class="Sub">2</span>- or PGF<span class="Sub">2α</span>-, mediated sensitization of the myometrium to oxytocin, systemic effects of PGE<span class="Sub">2</span> are rarely encountered.  The insert is fitted with a biocompatible retrieval system which facilitates removal at the conclusion of therapy or in the event of an adverse reaction.</p>
<p>No correlation could be established between PGE<span class="Sub">2</span> release and plasma concentrations of PGE<span class="Sub">m</span>.  The relative contributions of endogenously and exogenously released PGE<span class="Sub">2</span> to the plasma levels of the metabolite PGE<span class="Sub">m</span> could not be determined.  Moreover, it is uncertain as to whether the measured concentrations of PGE<span class="Sub">m</span> reflect the natural progression of PGE<span class="Sub">m</span> concentrations in blood as birth approaches or to what extent the measured concentrations following PGE<span class="Sub">2</span> administration represent an increase over basal levels that might be measured in control patients.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Cervidil Vaginal Insert (dinoprostone, 10 mg) is indicated for the initiation and/or continuation of cervical ripening in patients at or near term in whom there is a medical or obstetrical indication for the induction of labor.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Cervidil is contraindicated in:</p>
<dl class="Disc">
<dt>*</dt>
<dd> Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to prostaglandins.</dd>
<dt>*</dt>
<dd> Patients in whom there is clinical suspicion or definite evidence of <span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">fetal distress</span> where delivery is not imminent.</dd>
<dt>*</dt>
<dd> Patients with unexplained <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> during this pregnancy.</dd>
<dt>*</dt>
<dd> Patients in whom there is evidence or strong suspicion of marked cephalopelvic disproportion.</dd>
<dt>*</dt>
<dd><p class="First"> Patients in whom oxytocic drugs are contraindicated or when prolonged contraction of the uterus may be detrimental to fetal safety or uterine integrity, such as previous cesarean section or major uterine surgery <span class="Underline">(see</span><span class="Bold Underline"><a href="#s7">PRECAUTIONS</a></span><span class="Underline">and</span><span class="Bold Underline"><a href="#s14">ADVERSE REACTIONS</a></span><span class="Underline">).</span></p></dd>
<dt>*</dt>
<dd> Patients already receiving intravenous oxytocic drugs.</dd>
<dt>*</dt>
<dd> Multipara with 6 or more previous term pregnancies.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Italics Underline">For hospital use only</span></p>
<p>Cervidil should be administered only by trained obstetrical personnel in a hospital setting with appropriate obstetrical care facilities.</p>
<p>

Women aged 30 years or older, those with complications during pregnancy and those with a gestational age over 40 weeks have been shown to have an increased risk of postpartum <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>. In addition, these factors may further increase the risk associated with labor induction (See <span class="Bold"><a href="#s14">ADVERSE REACTIONS</a></span>, Post-marketing surveillance). Therefore, in these women, use of dinoprostone should be undertaken with caution. Measures should be applied to detect as soon as possible an evolving <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> in the immediate post-partum period.</p>
<p>

The Clinician should be alert that use of dinoprostone may result in inadvertent disruption and subsequent embolization of antigenic tissue causing in rare circumstances the development of <span class="product-label-link" type="condition" conceptid="435616" conceptname="Amniotic fluid embolism">Anaphylactoid Syndrome of Pregnancy</span> (<span class="product-label-link" type="condition" conceptid="435616" conceptname="Amniotic fluid embolism">Amniotic Fluid Embolism</span>).
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s8"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">1. General Precautions:</span> Since prostaglandins potentiate the effect of oxytocin, Cervidil must be removed before oxytocin administration is initiated and the patient's uterine activity carefully monitored for <span class="product-label-link" type="condition" conceptid="192698" conceptname="Hypertonic uterine dysfunction">uterine hyperstimulation</span>.  If <span class="product-label-link" type="condition" conceptid="192698" conceptname="Hypertonic uterine dysfunction">uterine hyperstimulation</span> is encountered or if labor commences, the vaginal insert should be removed.  Cervidil should also be removed prior to amniotomy.</p>
<p>Cervidil is contraindicated when prolonged contraction of the uterus may be detrimental to fetal safety and uterine integrity. Therefore, Cervidil should not be administered to patients with a history of previous cesarean section or uterine surgery given the potential risk for <span class="product-label-link" type="condition" conceptid="195328" conceptname="Rupture of uterus before onset of labor">uterine rupture</span> and associated obstetrical complications, including the need for hysterectomy and the occurrence of fetal or neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Caution should be exercised in the administration of Cervidil for cervical ripening in patients with ruptured membranes, in cases of non-vertex or non-singleton presentation, and in patients with a history of previous uterine hypertony, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, or a history of childhood <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, even though there have been no <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in adulthood.</p>
<p>Uterine activity, fetal status and the progression of cervical dilatation and effacement should be carefully monitored whenever the dinoprostone vaginal insert is in place.  With any evidence of <span class="product-label-link" type="condition" conceptid="192698" conceptname="Hypertonic uterine dysfunction">uterine hyperstimulation</span>, sustained uterine contractions, <span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">fetal distress</span>, or other fetal or maternal adverse reactions, the vaginal insert should be removed.</p>
<p>An increased risk of post-partum <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span> has been described in patients whose labor was induced by physiologic means, either with dinoprostone or oxytocin.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s9"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">2. Drug Interactions:</span> Cervidil may augment the activity of oxytocic agents and their concomitant use is not recommended.  A dosing interval of at least 30 minutes is recommended for the sequential use of oxytocin following the removal of the dinoprostone vaginal insert.  No other drug interactions have been identified.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s10"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold">3. Carcinogenesis, Mutagenesis, Impairment of Fertility:</span> Long-term carcinogenicity and fertility studies have not been conducted with Cervidil (dinoprostone) Vaginal Insert.  No evidence of mutagenicity has been observed with prostaglandin E<span class="Sub">2</span> in the Unscheduled DNA Synthesis Assay, the Micronucleus Test, or Ames Assay.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="s11"></a><a name="section-7.4"></a><p></p>
<h2>4. Pregnancy, Teratogenic Effects:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-7.4.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category C.</span></p>
<p>Prostaglandin E<span class="Sub">2</span> has produced an increase in skeletal anomalies in rats and rabbits.  No effect would be expected clinically, when used as indicated, since Cervidil (dinoprostone) Vaginal Insert is administered after the period of organogenesis.  Prostaglandin E<span class="Sub">2</span> has been shown to be embryotoxic in rats and rabbits, and any dose that produces sustained increased uterine tone could put the embryo or fetus at risk.</p>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s13"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold">5. Pediatric Use:</span> The safety and efficacy of Cervidil has been established in women of a reproductive age and women who are pregnant. Although safety and efficacy has not been established in pediatric patients, safety and efficacy are expected to be the same for adolescents.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s14"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Cervidil is well tolerated.  In placebo-controlled trials in which 658 women were entered and 320 received active therapy (218 without retrieval system, 102 with retrieval system), the following events were reported.</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1 Total Cervidil – Treated Drug Related Adverse Events</span></caption>
<col align="left" width="33.833%">
<col align="left" width="32.300%">
<col align="left" width="33.867%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">1</span>Controlled Studies (with and without retrieval system)</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">2</span>Controlled Study (with retrieval system)</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold Underline">Controlled Studies</span><span class="Sup">1</span>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top"><span class="Bold Underline">Active</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold Underline">Placebo</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="192698" conceptname="Hypertonic uterine dysfunction">Uterine hyperstimulation</span><br>with <span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">fetal distress</span></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">2.8%</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">0.3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="192698" conceptname="Hypertonic uterine dysfunction">Uterine hyperstimulation</span><br>without <span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">fetal distress</span></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">4.7%</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">0%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">Fetal Distress</span> without<br><span class="product-label-link" type="condition" conceptid="192698" conceptname="Hypertonic uterine dysfunction">uterine hyperstimulation</span></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">3.8%</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">1.2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="right" valign="top">N   </td>
<td class="Botrule Rrule" align="center" valign="top">320</td>
<td class="Botrule Rrule" align="center" valign="top">338</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold Underline">STUDY 101-801</span><span class="Sup">2</span>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top"><span class="Bold Underline">Active</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold Underline">Placebo</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="192698" conceptname="Hypertonic uterine dysfunction">Uterine hyperstimulation</span><br>with <span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">fetal distress</span></td>
<td class="Botrule Rrule" align="center" valign="top">2.9%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="192698" conceptname="Hypertonic uterine dysfunction">Uterine hyperstimulation</span><br>without <span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">fetal distress</span></td>
<td class="Botrule Rrule" align="center" valign="top">2.0%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">Fetal Distress</span> without<br><span class="product-label-link" type="condition" conceptid="192698" conceptname="Hypertonic uterine dysfunction">uterine hyperstimulation</span></td>
<td class="Botrule Rrule" align="center" valign="top">2.9%</td>
<td class="Botrule Rrule" align="center" valign="top">1.0%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="right" valign="top">N   </td>
<td class="Botrule Rrule" align="center" valign="top">102<br><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">104</td>
</tr>
</tbody>
</table>
<p>Drug related <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> were noted in less than 1% of patients who received Cervidil.</p>
<p>In study 101-801 (with the retrieval system) cases of hyperstimulation reversed within 2 to 13 minutes of removal of the product.  Tocolytics were required in one of the five cases.</p>
<p>In cases of <span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">fetal distress</span>, when product removal was thought advisable there was a return to normal rhythm and no neonatal sequelae.</p>
<p>Five minute Apgar scores were 7 or above in 98.2%  (646/658) of studied neonates whose mothers received Cervidil.  In a report of a 3 year pediatric follow-up study in 121 infants, 51 of whose mothers received Cervidil, there were no deleterious effects on physical examination or psychomotor evaluation (18).</p>
<p>
Post-marketing surveillance:</p>
<p>
<span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></p>
<p>
Blood and lymphatic system disorders: <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">Disseminated Intravascular Coagulation</span> (See <a href="#s6">Warnings</a> Section)</p>
<p>
Reproductive system: Reports of <span class="product-label-link" type="condition" conceptid="195328" conceptname="Rupture of uterus before onset of labor">uterine rupture</span> have been reported in association with use of Cervidil some required a hysterectomy and some resulted in subsequent fetal or neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>
<span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> </p>
<p>Pregnancy, Puerperium and Perinatal Conditions: <span class="product-label-link" type="condition" conceptid="435616" conceptname="Amniotic fluid embolism">Amniotic fluid embolism</span> </p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="s15"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">No drug abuse or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> has been seen with the use of Cervidil.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s16"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Cervidil is used as a single dosage in a single application.  Overdosage is usually manifested by <span class="product-label-link" type="condition" conceptid="192698" conceptname="Hypertonic uterine dysfunction">uterine hyperstimulation</span> which may be accompanied by <span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">fetal distress</span>, and is usually responsive to removal of the insert.  Other treatment must be symptomatic since, to date, clinical experience with prostaglandin antagonists is insufficient.</p>
<p>The use of beta-adrenergic agents should be considered in the event of undesirable increased uterine activity.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s17"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dosage of dinoprostone in the vaginal insert is 10 mg designed to be released at approximately 0.3 mg/hour over a 12 hour period.  Cervidil should be removed upon onset of active labor or 12 hours after insertion.</p>
<p>Cervidil is supplied in an individually wrapped aluminium/polyethylene package with a "tear mark" on one side of the package. The package should only be opened by tearing the aluminium package along the tear mark. The package should never be opened with scissors or other sharp objects which may compromise or cut the knitted polyester pouch that serves as the retrieval system for the polymeric slab.</p>
<p>Cervidil must be kept frozen until use, and is administered by placing one unit  transversely in the posterior fornix of the vagina immediately after removal from its foil package.  The insertion of the vaginal insert does not require sterile conditions.  The vaginal insert must not be used without its retrieval system.  There is no need for previous warming of the product.  A minimal amount of water-miscible lubricant may be used to assist insertion of Cervidil.  Care should be taken not to permit excess contact or coating with the lubricant which could prevent optimal <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and release of dinoprostone from the vaginal insert.  Patients should remain in the recumbent position for 2 hours following insertion, but thereafter may be ambulatory.  If the patient is ambulatory, care should be taken to ensure the vaginal insert remains in place. If <span class="product-label-link" type="condition" conceptid="192698" conceptname="Hypertonic uterine dysfunction">uterine hyperstimulation</span> is encountered or if labor commences, the vaginal insert should be removed. Cervidil should also be removed prior to amniotomy.</p>
<p>Upon removal of Cervidil, it is essential to ensure that the slab has been removed, as it will continue delivering the active ingredient.  This is accomplished by visualizing the knitted polyester retrieval system and confirming that it contains the slab.  In the rare instance that the slab is not contained within the polyester retrieval system, a vaginal exam should be performed to remove the slab.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s18"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Cervidil (NDC 0456-4123-63) contains 10 mg dinoprostone.  The product is <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> and enclosed in an aluminium/polyethylene pack.</p>
<p>Store in a freezer: between -20°C and -10°C (-4°F and 14°F).  Cervidil is packed in foil and is stable when stored in a freezer for a period of three years.  Vaginal inserts exposed to high humidity will absorb moisture from the air and thereby alter the release characteristics of dinoprostone.  Once used, the vaginal insert should be discarded.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="e18"></a><a name="section-13"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<a name="t2"></a><table width="100%">
<caption><span>Table 2 Efficacy of Cervidil in Double Blind Studies</span></caption>
<col align="left" width="18.305%">
<col align="left" width="20.306%">
<col align="left" width="11.775%">
<col align="left" width="11.775%">
<col align="left" width="11.775%">
<col align="left" width="13.032%">
<col align="left" width="13.032%">
<thead>
<tr class="First">
<th class="Botrule" align="center" valign="top"></th>
<th class="Botrule Rrule" align="center" valign="top"></th>
<th class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold Underline">Primip/Nullip</span></th>
<th class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold Underline">Multip</span></th>
<th class="Botrule Rrule" align="center" valign="top"></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold Underline">Parameter</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold Underline">Study #</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold Underline">Cervidil</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold Underline">Placebo</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold Underline">Cervidil</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold Underline">Placebo</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold Underline">P-Value</span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">*</span>Treatment success was defined as Bishop score increase at 12 hours of≥ 3, vaginal delivery within 12 hours or Bishop score at 12 hours≥ 6.  These studies were not designed with the power to show differences in cesarean section rates between Cervidil and placebo groups and none were noted.</p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" rowspan="3" valign="top">Treatment Success<span class="Sup">*</span>
</td>
<td class="Rrule" align="center" valign="bottom">101-103 (N=81)</td>
<td class="Rrule" align="center" valign="bottom">65%</td>
<td class="Rrule" align="center" valign="bottom">28%</td>
<td class="Rrule" align="center" valign="bottom">87%</td>
<td class="Rrule" align="center" valign="bottom">29%</td>
<td class="Rrule" align="center" valign="bottom">&lt;0.001</td>
</tr>
<tr>
<td class="Rrule" align="center" valign="bottom">101-003<br>(N=371)</td>
<td class="Rrule" align="center" valign="bottom">68%</td>
<td class="Rrule" align="center" valign="bottom">24%</td>
<td class="Rrule" align="center" valign="bottom">77%</td>
<td class="Rrule" align="center" valign="bottom">24%</td>
<td class="Rrule" align="center" valign="bottom">&lt;0.001</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom">101-801<br>(N=206)</td>
<td class="Botrule Rrule" align="center" valign="bottom">72%</td>
<td class="Botrule Rrule" align="center" valign="bottom">48%</td>
<td class="Botrule Rrule" align="center" valign="bottom">55%</td>
<td class="Botrule Rrule" align="center" valign="bottom">41%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.003</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">Time to Delivery (hours)</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Average Median</td>
<td class="Botrule Rrule" align="center" valign="top">101-103 (N=81)</td>
<td class="Botrule Rrule" align="center" valign="top">33.7<br>25.7</td>
<td class="Botrule Rrule" align="center" valign="top">48.6<br>34.5</td>
<td class="Botrule Rrule" align="center" valign="top">14.0<br>12.3</td>
<td class="Botrule Rrule" align="center" valign="top">28.6<br>24.6</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>0.001</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Average Median</td>
<td class="Botrule Rrule" align="center" valign="top">101-801<br>(N=206)</td>
<td class="Botrule Rrule" align="center" valign="top">31.1<br>25.5</td>
<td class="Botrule Rrule" align="center" valign="top">51.8<br>37.2</td>
<td class="Botrule Rrule" align="center" valign="top">52.3<br>20.8</td>
<td class="Botrule Rrule" align="center" valign="top">45.9<br>27.4</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>&lt;0.001</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">Time to Onset of Labor (hrs)</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Average Median</td>
<td class="Botrule Rrule" align="center" valign="top">101-103 (N=81)</td>
<td class="Botrule Rrule" align="center" valign="top">19.9<br>12.0</td>
<td class="Botrule Rrule" align="center" valign="top">39.4<br>19.2</td>
<td class="Botrule Rrule" align="center" valign="top">6.8<br>6.9</td>
<td class="Botrule Rrule" align="center" valign="top">22.4<br>18.3</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>&lt;0.001</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s19"></a><a name="section-14"></a><p></p>
<h1>References</h1>
<ol class="Arabic">
<li>Physiology of Labor In: Williams Obstetrics. Eds. Pritchard, J. A., MacDonald, P. C., and Gant, N.F. Appleton-Century-Crofts, Conn, Pp 295-321, (1985).</li>
<li>Rall, T. W. and Schliefer, L. S.  Oxytocin, prostaglandin, ergot alkaloids, and other drugs; tocolytics agents, In:  The Pharmacological Basis of Therapeutics.  Eds. Gilman, A.G., Goodman, L.S., Rall, T.W., and Murad, F. MacMillan, Publ. Co., New York, Pp. 926-945, (1985).</li>
<li>Casey, M.L. and MacDonald, P.C.  The initiation of labor in women: Regulation of phospholipid and arachidonic acid metabolism and of prostaglandin production.  Semin. Perinat. 10:270-275, (1986).</li>
<li>Casey, M.L., MacDonald, P.C. and Mitchell, M.D.  Stimulation of Prostaglandin E<span class="Sub">2</span> production in amnion cells in culture by a substance(s) in human fetal urine.  Biochem.  Biophys. Res. Comm.  114:1056, (1983).</li>
<li>Olson, C.M., Lye, S.J., Skinner, K. and Challis, J.R.G.  Prostanoid concentrations in maternal/fetal plasma and amniotic fluid and intrauterine tissue prostanoid output in relation to myometrial contractility during the onset of Endocrinology, 116: 389-397, (1985).</li>
<li>Ledger, W.L., Ellwood, D.A., and Taylor, M.J.  Cervical softening in late pregnant sheep by infusion of Prostaglandin E<span class="Sub">2</span> into cervical artery.  J. Reprod. Fert. 69, 511-515, (1983).</li>
<li>Olson, D.M., Lye, S.J., Skinner, K. and Challis, J.R.G.  Early changes in prostaglandin concentrations in ovine maternal and fetal plasma, amniotic fluid and from dispersed cells of intrauterine tissues before the onset of ACTH-induced pre-term labor.  J. Reprod. Fert., 71: 45-55, (1984).</li>
<li>Caldero-Garcia, R. and Posiero, J.  Oxytocin and the contractility of the human uterus,  Ann, N. Y. Acad. Sci. 75:813, (1959).</li>
<li>Posiero, J. and Noriega-Guerra, L.  Dose-response relationships in uterine effects of oxytocin infusion.  Oxytocin. Eds., Caldero-Garcia, R. and Heller, J. Pergamon Press, New York, (1961).</li>
<li>Cibils, L.  Enhancement of induction of labor.  In: Risks in the Practice of Modern Obstetrics. Aldjem, S. Ed. Mosby Publishing, St. Louis, (1972).</li>
<li>Bryman, I., Lindblom, B., and Norstrom, A.  Extreme sensitivity of cervical musculature to prostaglandin E<span class="Sub">2</span> in early pregnancy.  Lancet, 2:1471, (1982).</li>
<li>Thiery, M.  Induction of labor with prostaglandins.  In: Human Parturition. Eds. Keirse, M.J.N.C., Anderson, A.B.M., and Gravenhorst, J.B. Martinus Nijhoff Publ., Boston, 155-164, (1979).</li>
<li>Thiery, M. and Amy, J.J. Induction of labor with prostaglandins.  In:Advances in Prostaglandin Research.  Prostaglandin and Reproduction, Karim, S.M.M., Ed., MTP, Lancaster, Pp. 149-228, (1975).</li>
<li>MacLennan, A.H., Katz, M.,  and Creasey, R.  The morphologic characteristics of cervical ripening induced by the hormones relaxin and prostaglandin F<span class="Sub">2</span> in a rabbit model.  Am. J. Obstet. Gynecol, 152:910696, (1985).</li>
<li>Bishop, E.  Elective induction of labor.  Obstet &amp; Gynecol, 5: 519-527, (1955).</li>
<li>Bishop, E. Pelvic scoring for elective induction.  Obstet &amp; Gynecol. 24: 266-268, (1969).</li>
<li>Thiery, M.  Preinduction cervical ripening.  In:  Obstetrics and Gynecology Annual, Vol. 12, Ed. Wynn, R. M. Appleton-Century-Crofts, New York, Pp. 103-146, (1983).</li>
<li>MacKenzie, I.;  Information on File: Controlled Therapeutics (Scotland).</li>
<li>De Abajo FJ et al. Labor induction with dinoprostone or oxytocin and postpartum <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>: a hospital-based case-control study. Am J Obs Gynecol, 2004, 191: 1637-1643.</li>
</ol>
<p class="First">Mfg by:<br>Ferring Controlled Therapeutics Limited<br>East Kilbride, Scotland, G74 5PB</p>
<p>Made in the U.K.</p>
<p>Distributed by:<br>FOREST PHARMACEUTICALS, INC.<br>Subsidiary of Forest Laboratories, Inc.<br>St. Louis, MO 63045 USA</p>
<p>Rev. 10/12             RMC 226</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="d1"></a><a name="section-15"></a><p></p>
<h1>Principal Display Panel
</h1>
<p class="First"><span class="Bold">PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - PACKAGE CARTON</span></p>
<p>CERVIDIL®
</p>
<p>DINOPROSTONE 10 mg
</p>
<p>vaginal insert
</p>
<p>KEEP FROZEN
</p>
<p>Made in the U.K.
</p>
<p>Distributed by:
</p>
<p>FOREST PHARMACEUTICALS, INC.
</p>
<p>Subsidiary of Forest Laboratories, Inc.
</p>
<p>St. Louis, MO  63045
</p>
<div class="Figure">
<a name="f02"></a><img alt="PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - PACKAGE CARTON
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f1391c7c-233e-44d8-8838-36cc12f01044&amp;name=cer00-0004-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="d2"></a><a name="section-16"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - Unit Carton
</h1>
<p class="First">NDC 0456-4123-63
</p>
<p>CERVIDIL®
</p>
<p>DINOPROSTONE 10 mg
</p>
<p>vaginal insert
</p>
<p>Contains:  One Cervidil® Vaginal Insert containing
</p>
<p>10 mg Dinoprostone in 241 mg hydrogel polymer
</p>
<p>(cross-linked polyethylene oxide/urethane)
</p>
<p>With polyester retrieval system.
</p>
<p>Store in freezer:  between -20C and -10C (-4F and 14F)
</p>
<div class="Figure">
<a name="f03"></a><img alt="PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - Unit Carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f1391c7c-233e-44d8-8838-36cc12f01044&amp;name=cer00-0004-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="d3"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - Packet
</h1>
<p class="First">Bar Code 04564    12363
</p>
<p>CERVIDIL®
</p>
<p>DINOPROSTONE 10 mg
</p>
<p>vaginal insert
</p>
<p>FOREST PHARMACEUTICALS, INC.
</p>
<p>St. Louis, MO  63045, Made in the UK.
</p>
<div class="Figure">
<a name="f04"></a><img alt="PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - Packet
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f1391c7c-233e-44d8-8838-36cc12f01044&amp;name=cer00-0004-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CERVIDIL 		
					</strong><br><span class="contentTableReg">dinoprostone insert, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0456-4123</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">VAGINAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Dinoprostone</strong> (Dinoprostone) </td>
<td class="formItem">Dinoprostone</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0456-4123-63</td>
<td class="formItem">1  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 PACKET; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020411</td>
<td class="formItem">05/19/1995</td>
<td class="formItem">12/31/2015</td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Forest Laboratories, Inc.
							(001288281)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Ferring Controlled Therapeutics Ltd</td>
<td class="formItem"></td>
<td class="formItem">298229634</td>
<td class="formItem">MANUFACTURE(0456-4123)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>36e5c320-961b-4628-966e-85a35a6fad72</div>
<div>Set id: f1391c7c-233e-44d8-8838-36cc12f01044</div>
<div>Version: 6</div>
<div>Effective Time: 20100421</div>
</div>
</div> <div class="DistributorName">Forest Laboratories, Inc.</div></p>
</body></html>
